Description

VILDAMAC M 50/500 MG (1X15)

Indications

VILDAMAC M 50/500 MG is primarily indicated for the management of type 2 diabetes mellitus in adults. This medication is particularly beneficial for patients who have not achieved adequate glycemic control through diet and exercise alone. It is often prescribed in conjunction with other antidiabetic agents when necessary to improve glycemic control. VILDAMAC M combines two active ingredients, vildagliptin and metformin, which work synergistically to enhance blood glucose regulation.

Mechanism of Action

VILDAMAC M contains vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Vildagliptin works by increasing the levels of incretin hormones, which are responsible for stimulating insulin secretion in response to meals. This action helps to lower blood glucose levels by enhancing insulin release from the pancreas and reducing glucagon secretion. Metformin, on the other hand, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, thereby facilitating better glucose uptake and utilization. The combination of these two mechanisms results in improved glycemic control in patients with type 2 diabetes.

Pharmacological Properties

The pharmacokinetics of VILDAMAC M involve the absorption, distribution, metabolism, and excretion of its components. Vildagliptin is rapidly absorbed, with peak plasma concentrations occurring within 1-2 hours after oral administration. It has a half-life of approximately 2 hours and is primarily eliminated through renal excretion. Metformin is absorbed more slowly, with peak plasma concentrations reached within 2-3 hours. It is not metabolized but is excreted unchanged in the urine. The combination of these properties allows for effective and sustained glycemic control in patients.

Contraindications

VILDAMAC M is contraindicated in patients with a known hypersensitivity to either vildagliptin or metformin. It should not be used in individuals with severe renal impairment (eGFR < 30 mL/min), acute or chronic metabolic acidosis, including diabetic ketoacidosis, or in patients with a history of lactic acidosis. Additionally, caution is advised in patients with liver dysfunction, as this may increase the risk of lactic acidosis. Pregnant and breastfeeding women should also avoid this medication unless specifically directed by a healthcare provider.

Side Effects

Common side effects associated with VILDAMAC M include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms are often transient and may improve with continued use. Other potential side effects include headache, dizziness, and fatigue. A rare but serious side effect is lactic acidosis, which can occur, particularly in patients with renal impairment or other risk factors. Patients should be monitored for signs of lactic acidosis, such as muscle pain, respiratory distress, or unusual fatigue.

Dosage and Administration

The recommended starting dose of VILDAMAC M is typically one tablet taken orally once daily, preferably with food to minimize gastrointestinal side effects. The dosage may be adjusted based on the patient’s glycemic response and tolerance, with a maximum recommended dose of two tablets daily. It is essential to follow the healthcare provider’s instructions regarding dosage adjustments and to monitor blood glucose levels regularly to ensure optimal control.

Interactions

VILDAMAC M may interact with other medications, which can affect its efficacy or increase the risk of side effects. Concomitant use of diuretics, corticosteroids, or other medications that affect renal function may increase the risk of lactic acidosis. Additionally, the use of other antidiabetic agents, such as insulin or sulfonylureas, may require dose adjustments to avoid hypoglycemia. It is crucial for patients to inform their healthcare providers of all medications they are taking to manage potential interactions effectively.

Precautions

Patients taking VILDAMAC M should be closely monitored for signs of renal impairment, especially in older adults or those with pre-existing kidney conditions. Regular assessments of renal function are recommended to ensure safe use of the medication. Additionally, patients should be advised to maintain adequate hydration to reduce the risk of lactic acidosis. It is also important to educate patients about the signs and symptoms of hypoglycemia and lactic acidosis, ensuring they know when to seek medical attention.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of VILDAMAC M in managing type 2 diabetes. In randomized controlled trials, patients treated with VILDAMAC M showed significant reductions in HbA1c levels compared to those receiving placebo or monotherapy with either vildagliptin or metformin alone. The combination therapy was also associated with a favorable weight profile and a low incidence of hypoglycemia. Long-term studies indicated that VILDAMAC M effectively maintained glycemic control over extended periods, highlighting its role in the comprehensive management of type 2 diabetes.

Conclusion

VILDAMAC M 50/500 MG is a valuable therapeutic option for patients with type 2 diabetes mellitus, offering a dual mechanism of action that enhances glycemic control. Its combination of vildagliptin and metformin provides a synergistic effect, improving insulin secretion and sensitivity while reducing hepatic glucose production. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions. Regular monitoring of renal function and blood glucose levels is crucial for the safe and effective use of this medication. Overall, VILDAMAC M represents a significant advancement in diabetes management, helping patients achieve better health outcomes.